However, SGLT2 inhibitor had no effect in inhibiting the tumor growth and increasing the number of infiltrated immune cells in SGLT2 silenced osteosarcoma, which indicated that the anti-osteosarcoma effect SGLT2 inhibitor depended on the expression of SGLT2 (Fig. 3e–g). Here, SLC5A2 is linked to osteosarcoma.